Page 1 of 70
NR 565 ADVANCED PHARMACOLOGY FINAL EXAM
CHAMBERLAIN 2026/2027 COMPLETE (150) CURRENT
TESTING QUESTIONS AND CORRECT ANSWERS WITH
DETAILED RATIONALES.
PHARMACOLOGY
Prepare effectively for the Chamberlain NR 565 Final Exam in Advanced Pharmacology
with this focused study resource. It supports review of pharmacokinetics,
pharmacodynamics, medication classes, therapeutic effects, adverse reactions, drug
interactions, and safe prescribing principles. Use the material to reinforce your
pharmacology knowledge, review high-yield topics, and identify areas that may
require additional study. This resource is suited for Chamberlain nursing students,
advanced practice nursing learners, and candidates preparing for the NR 565
Advanced Pharmacology final examination.
MULTIPLE CHOICE.
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–
25)
1. The study of what the body does to a drug—including absorption,
distribution, metabolism, and excretion—is called:
• A. Pharmacodynamics
• B. Pharmacokinetics
• C. Pharmacotherapeutics
• D. Pharmacogenomics
Answer: B. Pharmacokinetics
Rationale: Pharmacokinetics is the study of drug movement throughout
the body, encompassing absorption, distribution, metabolism, and
excretion (ADME). Pharmacodynamics is the study of what the drug does
to the body (mechanism of action). Pharmacotherapeutics is the use of
drugs to treat disease.
, Page 2 of 70
2. Which pharmacokinetic parameter is defined as the proportion of an
administered drug that reaches systemic circulation in an unchanged
form?
• A. Volume of distribution
• B. Half-life
• C. Bioavailability
• D. Clearance
Answer: C. Bioavailability
Rationale: Bioavailability is the fraction of an administered dose of a drug
that reaches the systemic circulation unchanged. Intravenous
administration has 100% bioavailability. Oral bioavailability is reduced by
incomplete absorption and first-pass hepatic metabolism.
3. A drug with a half-life of 8 hours is administered at a dose of 200 mg.
Approximately how much of the drug will remain in the body after 24
hours?
• A. 100 mg
• B. 50 mg
• C. 25 mg
• D. 12.5 mg
Answer: C. 25 mg
Rationale: After each half-life, 50% of the drug remains. After 24 hours (3
half-lives): 200 mg → 100 mg → 50 mg → 25 mg. Half-life calculations are
essential for determining dosing intervals and time to steady state
(approximately 4–5 half-lives).
, Page 3 of 70
4. A patient with hepatic cirrhosis has decreased albumin production.
What change in the pharmacokinetics of a highly protein-bound drug
should the provider anticipate?
• A. Decreased free drug concentration
• B. Increased free drug concentration
• C. Decreased volume of distribution
• D. Increased renal excretion
Answer: B. Increased free drug concentration
Rationale: Hepatic cirrhosis reduces albumin synthesis, increasing the
unbound (free) fraction of highly protein-bound drugs. This can lead to
enhanced pharmacological effect and toxicity despite normal total drug
concentrations. Dosage reduction is often required.
5. Which CYP450 enzyme is responsible for metabolizing the largest
number of drugs (approximately 50%)?
• A. CYP2D6
• B. CYP2C9
• C. CYP3A4
• D. CYP1A2
Answer: C. CYP3A4
Rationale: CYP3A4 is the most abundant CYP450 enzyme in the liver and
intestines, metabolizing approximately 50% of all drugs. It is involved in
the metabolism of statins, calcium channel blockers, benzodiazepines,
and many other medications.
6. A patient is started on a medication that is a strong CYP3A4 inhibitor.
Which of the following drugs would require a dosage reduction due to this
interaction?
, Page 4 of 70
• A. Metformin
• B. Lisinopril
• C. Simvastatin
• D. Acetaminophen
Answer: C. Simvastatin
Rationale: Simvastatin is metabolized by CYP3A4. Co-administration with
a strong CYP3A4 inhibitor (e.g., ketoconazole, clarithromycin, grapefruit
juice) significantly increases simvastatin levels, increasing the risk of
myopathy and rhabdomyolysis. Simvastatin dose should be limited to 20
mg when used with strong CYP3A4 inhibitors.
7. What is the therapeutic index of a drug?
• A. The ratio of ED50 to LD50
• B. The ratio of the toxic dose to the therapeutic dose
• C. The dose required to produce a therapeutic effect in 50% of patients
• D. The time required for the drug to reach steady state
Answer: B. The ratio of the toxic dose to the therapeutic dose
Rationale: The therapeutic index (TI) is the ratio of the dose that produces
toxicity in 50% of the population (TD50) to the dose that produces a
therapeutic effect in 50% of the population (ED50). A narrow TI (e.g.,
warfarin, digoxin, lithium, phenytoin) requires careful monitoring to avoid
toxicity.
8. A drug that is a weak acid (pKa = 4.5) is administered orally. In the
stomach (pH ≈ 1.5), the drug will be:
• A. Primarily non-ionized and readily absorbed
• B. Primarily ionized and poorly absorbed
• C. Equally ionized and non-ionized
NR 565 ADVANCED PHARMACOLOGY FINAL EXAM
CHAMBERLAIN 2026/2027 COMPLETE (150) CURRENT
TESTING QUESTIONS AND CORRECT ANSWERS WITH
DETAILED RATIONALES.
PHARMACOLOGY
Prepare effectively for the Chamberlain NR 565 Final Exam in Advanced Pharmacology
with this focused study resource. It supports review of pharmacokinetics,
pharmacodynamics, medication classes, therapeutic effects, adverse reactions, drug
interactions, and safe prescribing principles. Use the material to reinforce your
pharmacology knowledge, review high-yield topics, and identify areas that may
require additional study. This resource is suited for Chamberlain nursing students,
advanced practice nursing learners, and candidates preparing for the NR 565
Advanced Pharmacology final examination.
MULTIPLE CHOICE.
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–
25)
1. The study of what the body does to a drug—including absorption,
distribution, metabolism, and excretion—is called:
• A. Pharmacodynamics
• B. Pharmacokinetics
• C. Pharmacotherapeutics
• D. Pharmacogenomics
Answer: B. Pharmacokinetics
Rationale: Pharmacokinetics is the study of drug movement throughout
the body, encompassing absorption, distribution, metabolism, and
excretion (ADME). Pharmacodynamics is the study of what the drug does
to the body (mechanism of action). Pharmacotherapeutics is the use of
drugs to treat disease.
, Page 2 of 70
2. Which pharmacokinetic parameter is defined as the proportion of an
administered drug that reaches systemic circulation in an unchanged
form?
• A. Volume of distribution
• B. Half-life
• C. Bioavailability
• D. Clearance
Answer: C. Bioavailability
Rationale: Bioavailability is the fraction of an administered dose of a drug
that reaches the systemic circulation unchanged. Intravenous
administration has 100% bioavailability. Oral bioavailability is reduced by
incomplete absorption and first-pass hepatic metabolism.
3. A drug with a half-life of 8 hours is administered at a dose of 200 mg.
Approximately how much of the drug will remain in the body after 24
hours?
• A. 100 mg
• B. 50 mg
• C. 25 mg
• D. 12.5 mg
Answer: C. 25 mg
Rationale: After each half-life, 50% of the drug remains. After 24 hours (3
half-lives): 200 mg → 100 mg → 50 mg → 25 mg. Half-life calculations are
essential for determining dosing intervals and time to steady state
(approximately 4–5 half-lives).
, Page 3 of 70
4. A patient with hepatic cirrhosis has decreased albumin production.
What change in the pharmacokinetics of a highly protein-bound drug
should the provider anticipate?
• A. Decreased free drug concentration
• B. Increased free drug concentration
• C. Decreased volume of distribution
• D. Increased renal excretion
Answer: B. Increased free drug concentration
Rationale: Hepatic cirrhosis reduces albumin synthesis, increasing the
unbound (free) fraction of highly protein-bound drugs. This can lead to
enhanced pharmacological effect and toxicity despite normal total drug
concentrations. Dosage reduction is often required.
5. Which CYP450 enzyme is responsible for metabolizing the largest
number of drugs (approximately 50%)?
• A. CYP2D6
• B. CYP2C9
• C. CYP3A4
• D. CYP1A2
Answer: C. CYP3A4
Rationale: CYP3A4 is the most abundant CYP450 enzyme in the liver and
intestines, metabolizing approximately 50% of all drugs. It is involved in
the metabolism of statins, calcium channel blockers, benzodiazepines,
and many other medications.
6. A patient is started on a medication that is a strong CYP3A4 inhibitor.
Which of the following drugs would require a dosage reduction due to this
interaction?
, Page 4 of 70
• A. Metformin
• B. Lisinopril
• C. Simvastatin
• D. Acetaminophen
Answer: C. Simvastatin
Rationale: Simvastatin is metabolized by CYP3A4. Co-administration with
a strong CYP3A4 inhibitor (e.g., ketoconazole, clarithromycin, grapefruit
juice) significantly increases simvastatin levels, increasing the risk of
myopathy and rhabdomyolysis. Simvastatin dose should be limited to 20
mg when used with strong CYP3A4 inhibitors.
7. What is the therapeutic index of a drug?
• A. The ratio of ED50 to LD50
• B. The ratio of the toxic dose to the therapeutic dose
• C. The dose required to produce a therapeutic effect in 50% of patients
• D. The time required for the drug to reach steady state
Answer: B. The ratio of the toxic dose to the therapeutic dose
Rationale: The therapeutic index (TI) is the ratio of the dose that produces
toxicity in 50% of the population (TD50) to the dose that produces a
therapeutic effect in 50% of the population (ED50). A narrow TI (e.g.,
warfarin, digoxin, lithium, phenytoin) requires careful monitoring to avoid
toxicity.
8. A drug that is a weak acid (pKa = 4.5) is administered orally. In the
stomach (pH ≈ 1.5), the drug will be:
• A. Primarily non-ionized and readily absorbed
• B. Primarily ionized and poorly absorbed
• C. Equally ionized and non-ionized
